ArticleFrontiers in chemistry2020
Identification of Chalcone Derivatives as Inhibitors of
Article in Frontiers in chemistry, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 13 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
13 citing papers in PubMed, 47 citations in OpenAlex.
- Cross-Species Hepatic Metabolism of the Antileishmanial Chalcone NAT22 Generates Metabolites with Predicted Enhanced Affinity for the Parasite Target cTXNPx.Pharmaceutics · 2026Article
- Computational and experimental studies to discover a promising lead compound, chemically related to natural acetylene acetogenins from Porcelia macrocarpa, against amastigotes of Leishmania (L.) infantum.Journal of computer-aided molecular design · 2025Article
- In Vitro and In Silico Assessments of Curcuminoids and Turmerones fromPharmaceuticals (Basel, Switzerland) · 2025Article
- Red-shifted optical absorption induced by donor-acceptor-donor π-extended dibenzalacetone derivatives.RSC advances · 2025Article
- Pharmacological potential of natural chalcones: a recent studies and future perspective.Frontiers in pharmacology · 2025Review
- In vitro and in silico approaches manifest the anti-leishmanial activity of wild edible mushroomIn silico pharmacology · 2025Article
- A colorimetric assay adapted to fragment screening revealing aurones and chalcones as new arginase inhibitors.RSC medicinal chemistry · 2024Article
- Evolution of the Quinoline Scaffold for the Treatment of Leishmaniasis: A Structural Perspective.Pharmaceuticals (Basel, Switzerland) · 2024Review
- Antiviral and antimicrobial applications of chalcones and their derivatives: From nature to greener synthesis.Heliyon · 2023Review
- The Natural Alkaloid Tryptanthrin Induces Apoptosis-like Death inTropical medicine and infectious disease · 2022Article
- Evolution of Acridines and Xanthenes as a Core Structure for the Development of Antileishmanial Agents.Pharmaceuticals (Basel, Switzerland) · 2022Review
- Total Synthesis of the Natural Chalcone Lophirone E, Synthetic Studies toward Benzofuran and Indole-Based Analogues, and Investigation of Anti-Leishmanial Activity.Molecules (Basel, Switzerland) · 2022Article
- Benzimidazole Derivatives as New and Selective Inhibitors of Arginase fromInternational journal of molecular sciences · 2021Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
11 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Arginase catalyzes the hydrolysis of l-arginine into l-ornithine and urea, acting as a key enzyme in the biosynthesis of polyamines.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.